Previous 10 | Next 10 |
– Company will host a conference call and webcast at 5:00 pm ET today – Synlogic, Inc. ( Nasdaq: SYBX ), a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, today reported its financial results for the first qu...
Synlogic, Inc. ( Nasdaq: SYBX ), a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, announced today that the Company will release its first quarter 2019 financial results after the market closes on Thursday, May 9, 2019. The press...
Thinly traded micro cap Synlogic (NASDAQ: SYBX ) is up 14% premarket, albeit on only 349 shares, in response to data on an oral formulation process for synthetic biotic candidate SYNB1618 for the potential treatment of phenylketonuria (PKU), an inborn error of metabolism char...
- Synlogic’s robust and reproducible lyophilization process provides a solid formulation of SYNB1618 with improved quality attributes, stability and minimal loss of viability compared to liquid formulation - Synlogic, Inc. , (Nasdaq: SYBX) a clinical stage company applyin...
Synlogic, Inc. , (Nasdaq: SYBX) a clinical-stage drug discovery and development company applying synthetic biology to probiotics to develop novel living medicines, today announced that data from its program to develop solid oral formulations of its Synthetic Biotic TM medicines w...
The following slide deck was published by Synlogic, Inc. in conjunction with this Read more ...
Synlogic, Inc . (Nasdaq: SYBX), a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, today announced the appointment of Scott Plevy, M.D., as Chief Scientific Officer. Dr. Plevy will have responsibility for Synlogic’...
The FDA has signed off on a Phase 1/2 clinical trial, pheNIX, evaluating Homology Medicines' ( FIXX +0.4% ) gene therapy candidate HMI-102 in adults with a rare inherited disorder called phenylketonuria (PKU), referred to as an inborn error of metabolism. More news on: Homology Medicin...
Synlogic (Nasdaq:SYBX) announced today that Aoife Brennan, M.B., B.Ch., Synlogic’s president and chief executive officer, will provide a corporate update at the 18th Annual Needham Healthcare Conference at 3:30 pm ET on Tuesday, April 9, 2019, in New York City. A live webcast ...
The following slide deck was published by Synlogic, Inc. in conjunction with this Read more ...
News, Short Squeeze, Breakout and More Instantly...
CAMBRIDGE, Mass., March 19, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, today reported financial results for the fourth quarter and full year ending December 31, 2023. The Company...
CAMBRIDGE, Mass., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, today announced that its Board of Directors (the “Board”) has approved the adoption of a limited dur...
A look at the top 10 most actives in the United States NanoString Technologies Inc. (NSTG) rose 97.9% to $0.23 on volume of 419,200,402 shares Sunworks Inc. (SUNW) rose 87.9% to $0.1022 on volume of 385,386,904 shares Green Giant Inc. (GGE) rose 15.4% to $0.0427 on volume of 208,454,257 s...